Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI (NCT07583784) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI
South Korea860 participantsStarted 2026-07-01
Plain-language summary
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).
Who can participate
Age range
19 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
. New or presumed new significant ST-T wave changes
. Development of pathological Q waves on electrocardiography.
. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.
. Intracoronary thrombus detected on angiography.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is specifically for people who have both atrial fibrillation and a heart attack — do my exact diagnoses match what this study is looking for, and would my doctor consider me a potential candidate to discuss once it opens?
2The trial is measuring something called 'net adverse clinical events,' which seems to weigh the risk of bleeding against the risk of clotting — can my doctor explain what that trade-off currently looks like for someone in my situation on standard antithrombotic therapy?
3Since the trial is listed as 'not yet recruiting,' how long might it be before it opens, and should I be making treatment decisions now rather than waiting to see if I could eventually discuss enrolling?
4This trial is testing an 'abbreviated' antithrombotic approach after a PCI procedure — can my doctor explain what the current standard duration of blood-thinning therapy would be for me, and what the known risks are of shortening it?
5Are there already published studies or guidelines on shortened antithrombotic therapy for patients with both AFib and a recent heart attack that my doctor could walk me through, so I understand what this trial is trying to add to the evidence?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
NACE (net adverse clinical events)
Timeframe: 1 year after the last patient enrollment